Injectable Naltrexone as 2nd Line OUD Treatment SSN (April 2022)
LONG-ACTING INJECTABLE NALTREXONE IS A SECOND-LINE TREATMENT FOR MOST INDIVIDUALS WITH OPIOID USE DISORDER
Opioid Treatment Act of 2022 SSN Statement. (Feb 2022)
RESTRICTIONS ON DISPENSING METHADONE FOR TAKE-HOME USE SHOULD NOT BE CODIFIED IN STATUTE
